Research states new therapeutic options for COVID-19 related blood clots

New therapeutic treatments for covid 19 related blood clots

COVID-19 blood clots are most commonly seen in persons who have been hospitalized with the condition. However, blood clots can form even when there is no injury. This is potentially harmful since the clot might impede blood flow within your blood arteries, potentially leading to consequences such as stroke or heart attack. Research states new therapeutic options for COVID-19-related blood clots. According to a short study conducted by Yale Cancer Center researchers, blood clots or thromboembolic problems in COVID-19 patients are associated with elevated levels of several proteins. These proteins are the reasons for blood clotting, this result is derived after comparison with blood clots (nonrelated to COVID-19). This research could lead to new therapeutic methods for people with COVID-19-related blood clots. The outcomes and findings were presented on 14^th Decemeber in Atlanta, Georgia, at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Blood was drawn from 48 inpatients between December 2020 and February 2021. Of these, 24 had a confirmed diagnosis of COVID-19 infection and arterial or venous thromboembolism. 17 had a COVID-19 infection but no arterial thrombosis and no venous thromboembolism. While 7 had arterial or venous thromboembolism but no COVID-19 infection. Researchers discovered that patients with COVID-19 who also had blood clots had greater levels of (many) proteins.

Read | US Research predicts COVID 19 vaccines ineffectiveness for Omicron

Tissue factor (One of these proteins), is traditionally linked with an injury to the vascular lining (endothelium), and the fact that it was higher in the blood of COVID-19 patients suggests a more substantial insult to the endothelium. Pentraxin-3 (Another protein), was shown to be greater in patients who had blood clots in the presence of COVID-19.

Endothelial cells produce this protein during inflammation, making it a sign of endothelial damage. Researchers discovered that two additional proteins, C2 and C5a, as well as lipocalin-2 and resistin, were elevated in COVID-19 patients who formed blood clots. Previous research has found that these proteins are markers of neutrophil activation in COVID-19 patients and that higher levels are related to more severe illnesses.

Read | Plant-based chewing gum will fight off COVID 19 transmission? Here what scientist says

Furthermore, levels of the proteins SAA and PECAM-1 were higher in patients who developed blood clots after taking COVID-19."Moving forward, we would like to assess a much larger number of proteins and include more patients in future trials," stated senior author Alexander B Pine, MD, Ph.D., Assistant Professor of Medicine (Hematology) at Yale Cancer Center.

He also said that "A similar proteomics method could also be used to analyze mechanisms and variables involved in the development of thrombosis in inflammatory illnesses other than COVID-19." Kelly Borges, Marcus Shallow, Prerak Juthani, Stephen Wang, MD MPH, Akash Gupta, MD, Hyung Chun, MD, and Alfred Lee, MD, Ph.D. are also Yale authors on the paper.

Read | Researcher says, COVID-19 Boosters can help in preventing the third wave

Ghar Ka Baidya is dedicated to provide you with all important information on latest developments, skin, hair and other beauty related topics. So, like & follow us on social media platforms. Share this post as much as you can so that we can provide you with such information more rapidly.